The tumor suppressor p53 plays an important role in response to DNA damage, including DNA repair. One DNA repair pathway, nucleotide excision repair (NER), has been well-documented to be regulated by p53. It seemed probable that p53 may aect other DNA repair pathways. We employed matched isogenic pairs of cell lines, wild-type or p53-de®cient, to investigate this question using methyl methanesulfonate (MMS), a basedamaging agent. Alkylation damage induced by MMS is repaired exclusively by the base excision repair (BER) pathway. Cells carrying mutant or no p53 genes exhibited slow BER of MMS-induced DNA damage, and exhibited MMS-sensitivity. One contributing factor is the abundance of DNA polymerase b (b-pol), an enzyme required for BER, which was almost absent in p53 mutant and p53-null cells. Our ®ndings demonstrate an in vivo requirement for p53 in regulating the base excision repair response, a novel ®nding of great potential importance in understanding the DNA repair branch of the p53 pathway.
Introduction
The p53 tumor suppressor has long been envisaged to preserve genetic stability by induction of cell cycle checkpoints and enhancment of DNA repair (Kastan et al., 1992) . More recently, p53 and its downstream genes have been found to play direct roles in DNA repair responses to UV-radiation and other DNAdamaging agents, perhaps independent of cell cycle arrest responses to DNA damage (Smith et al., 2000; Oer et al., 2001a; Zhou et al., 2001) . UV-damage, and damage caused by certain cancer chemotherapeutics including cisplatin and nitrogen mustards, is repaired by the nucleotide excision repair (NER) pathway, known to be regulated by p53 and its downstream genes (Smith et al., , 2000 Hwang et al., 1999) . In the current study, we explore cellular responses to the base-damaging agent methyl methanesulfonate (MMS), a pure base-damaging agent that produces DNA damage that is repaired by the base excision repair (BER) pathway. Our ®ndings suggest that p53 regulates at least two major DNA repair pathways, NER and BER, which together account for the vast majority of DNA damages encountered in the environment.
One similarity between NER and BER is that both processes are carried out by multiprotein complexes. The NER repair complex is composed of approximately 20 proteins (Friedberg et al., 1995) , while the BER repair complex contains fewer subunits (Matsumoto et al., 1999) . A second similarity is that incision is required to occur on the damaged DNA strand, with subsequent resynthesis of the correct sequence information using the complementary strand as a template. The repair patch size diers, however, in that the BER repair patch is 1 ± 6 bases in length, while NER produces repair patches of approximately 30 bases in length (Friedberg et al., 1995) . The multiprotein complexes that carry out BER and NER dier for most of the subunits, even though a few such as proliferating cell nuclear antigen (PCNA) and XP-G (the product of the xeroderma pigmentosum complementation group G gene) are found in both BER and NER repair complexes (Matsumoto et al., 1999; Klungland et al., 1999) . Both repair complexes contain a DNA polymerase with which to conduct repair synthesis, DNA polymerases e and d in the case of NER, and DNA polymerase b in the case of BER (Stucki et al., 1998) .
The p53 tumor suppressor regulates perhaps as many as 100 proteins, many of which are involved in mediating cellular responses to DNA damage (Tokino et al., 1994) . We provide evidence that cellular BER is signi®cantly diminished in cells lacking functional p53, suggesting that p53 plays an active role in the BER complex.
Results

Alkaline comet assays show BER defect in p53-mutants
We employed matched isogenic pairs of cell lines, wildtype or p53-defective as in our earlier studies (Smith et al., , 2000 , and measured cellular BER responses by the use of methyl methanesulfonate (MMS), a well-known BER inducing agent (Friedberg et al., 1995) . MMS causes extensive methylation of the N7 position of guanine residues, and produces other alkylation damages, that are then processed by cellular glycosylases resulting in the generation of apurinic sites. The alkaline comet assay measures single-strand breaks associated with (alkali-labile) apurinic sites that are intermediates in the BER process (6 h after DNA damage; Figure 1 ). The relative fraction of singlestrand breaks (unrepaired or incompletely repaired sites) per genome equivalent (i.e. per single-cell basis) was determined from analysis of more than 600 cells for each data point (Figure 1a,c) . A subset of the population was then subjected to digital image analysis to determine tail moments from analysis of more than 50 cells for each DNA damage dose (Figure 1b,d ). P53-mutant cells exhibited an approximate threefold reduction of repair of MMS-induced DNA damage compared to wild-type cells. Asynchronous cells were predominantly in the G1 phase of the cell cycle, determined by FACS analysis (approximately 50% in G1) which could be distinguished visually from S or G2 cells (Smith et al., 2000) . A separate series of experiments were conducted in which serum-starved (G o ) cells were employed, which yielded similar results (not shown). Figure 1 shows experiments conducted in the RKO cell system, in which p53-regulation of NER was ®rst shown . We also utilized wild-type and p53-null mouse embryo ®broblasts (MEFs), which yielded similar results (Figure 1e) . Thus, the rate of BER is impaired in cells lacking functional p53 (Figure 1 ).
Included as a control, to ascertain that cells received equivalent DNA damage at time-zero, cells were treated with E. coli exonuclease III (Trevigen Inc., Gaithersburg, MD, USA) immediately after MMS treatment. The exonuclease is a homologue of APE that cleaves the damaged sites independent of the cellular repair capability. The initial amount of DNA damage was equal in wild-type and mutant cells (not shown). 
Lack of apoptosis or cell cycle arrest
In order to address whether cells treated with MMS would exhibit cell cycle dierences, which might not correspond between p53 wild-type and p53-mutant cells, we conducted¯ow cytometric analysis of MMStreated cells. No evidence of cell cycle arrest was observed up to 6 h after MMS treatment ( Figure 2 ). Moreover, no dierences were observed in comparing p53-wild-type and p53-mutant cells ( Figure 2 ). We also considered whether appreciable cell death occurred during the course of the experiments. Cells were treated with 200 mM MMS, then stained with Trypan blue 6 h after DNA damage. Percentages of viable p53 wildtype and mutant cells determined by Trypan blue exclusion, respectively, were 96.4 (+1.2)% and 95.7 (+3.3)% (mean+s.d. of ®ve determinations; results not shown), consistent with the¯ow cytometry data in which a sub-G1 fraction was not observed (Figure 2 ). Thus, neither cell cycle arrest nor apoptosis or other cell death appear to contribute to the BER defect after 2 ± 6 h as shown in Figure 1 .
By using 12-day clonogenic cell survival assays , we found that p53-mutant cells were more sensitive to MMS than their p53-wild-type counterparts (results not shown). MMS-sensitivity is consistent with a BER defect, even though long-term (12 day) cell survival is more complex. We determined levels of base damage remaining after 24 h, and found that 15 ± 25% of the base damage remains unrepaired in p53-mutant cells for at least 24 h (one complete cell cycle). Hence, our assays measure DNA repair at time points up to 6 h after MMS treatment (Figures 1 and  2 ). At later times (24 h), cells that retain DNA damage (i.e. p53-mutant cells) are likely to exit the cell cycle and succumb to apoptotic or other cell death, consistent with the ®nding that p53-mutant cells were MMS-sensitive in clonogenic assays (Lackinger and Kaina, 2001 and our data not shown).
APE is not affected by p53 status
We weighed potential mechanisms by which p53 protein could directly contribute to BER. One possible mechan- Figure 2 Flow cytometric analysis of p53 wild-type and -de®cient cells after MMS treatment. RKO cells were treated with 200 mM MMS for the indicated times, and subjected to¯ow cytometry. Cell number is plotted on the y axis; DNA content on the x axis. Cell cycle pro®les were indistinguishable in comparing p53 wild-type and p53-mutant cells. Note too the absence of a sub-G1 peak associated with apoptosis. Other measures of cell death, such as Trypan blue staining, likewise indicated that cells were 495% viable 6 h after MMS treatment, consistent with the cell cycle pro®les. Red, G1 peak; blue, G2 peak; crosshatched, S phase fraction ism is suggested by the ®nding that p53 interacts with apurinic endonuclease (APE; Jayaraman et al., 1997) a necessary BER enzyme that generates an incision on the damaged strand on the 5' end of the abasic site (Evans et al., 2000) . For example, one could envision that APE enzyme activity might be enhanced by complex formation with wild-type p53 protein, thereby having decreased activity in cells lacking p53. Assays to measure speci®cally APE-generated cleavage were conducted, using nuclear extracts of p53 wild-type and p53-null cells. Experiments were conducted over a wide range of extract concentrations. However, no dierences in APE cleavage were observed ( Figure 3 , and results not shown).
Expression of BER proteins in p53-deficient cells
We investigated other potential mechanisms by which p53 could contribute to BER. To determine if protein expression of BER-related proteins diered in the presence or absence of p53, Western blot analysis was performed. Relative protein expression of APE, ap endonuclease 1 (Fen-1), or PCNA was not aected by the p53 status of the cell. Although DNA polymerase-beta (b-pol), an enzyme required for new strand synthesis in BER, showed markedly reduced expression in p53-de®cient cells (Figure 4) . Thus, the lack of expression of b-pol correlates with the BER defect observed in p53-de®cient cells.
Discussion
Process of BER N 7 -methylguanine and 3-methyladenine are primary lesions induced by MMS treatment, which are then processed by N-methylpurine DNA glycosylase (MPG) to yield apurinic sites recognized by APE endonuclease. APE incises the damaged strand immediately 5' of the AP site. The DNA polymerase-b enzyme then ®lls in the incised repair patch, and it also participates in removing the overhang created by the displaced strand (Wilson and Kunkel, 2000) . An additional component of the second excision event is¯ap endonuclease-1 (Fen-1, discussed below). Ligation then completes the repair process. It has not long been known which of the steps are rate-limiting for BER, although recent studies have been focused on b-polymerase. Speci®-cally, mice lacking b-pol genes exhibit a BER-defective phenotype and MEFs derived from b-pol-null mice exhibited MMS-sensitivity (Wilson and Kunkel, 2000) . These studies suggested a critical rate-limiting role for b-pol in the process of BER.
Potential direct roles for p53
In the case of NER, p53 aects DNA repair through regulation of downstream eector genes such as Gadd45 (Smith et al., 2000; Hollander et al., 2001) and p48-XPE, the gene responsible for the xeroderma pigmentosum type E DNA repair de®cit (Hwang et al., . A direct role for p53 in NER has been implied, but has been dicult to demonstrate. Speci®cally, addition of recombinant p53 to assays of NER in vitro did not enhance NER (Leveillard et al., 1996) . On the other hand, extracts prepared from p53 wild-type or -defective cells did show dierent capacities to repair a UV-damaged plasmid template in vitro . Extracts from p53-de®cient cells exhibited an approximate threefold reduction in repair capacity by in vitro assays, in agreement with results obtained using other types of DNA repair assays Hanawalt, 1995, 1997) , and consistent with decreased expression of p53-regulated proteins involved in NER (Hwang et al., 1999) . In the case of BER, the addition of recombinant p53 did stimulate DNA repair in vitro (Oer et al., 2001b) , and a role for b-pol was suggested (Zhou et al., 2001 ). Indeed, evidence was shown for a direct interaction of p53 and b-pol proteins in vitro (Zhou et al., 2001) . Interestingly, p53 has also been shown to interact with APE (Jayaraman et al., 1997) which led us to investigate whether the p53 status of a given cell line would aect APE activity. However, extracts prepared from p53 wild-type and -de®cient cells showed no detectable dierences in APE activity, as measured by cleavage of an oligonucleotide substrate containing an apurinic site (Figure 3) . Thus, p53 does not appear to aect the step of the BER process involving APE incision. We turned attention to b-pol as a possible target of p53, in line with recent reports of a ratelimiting role for b-pol in BER (Sobol et al., 2000) .
We conducted Western blots of b-pol proteins in p53 wild-type and -de®cient cell lines. Levels of b-pol were markedly lower in p53-de®cient cells (Figure 4) . The mechanism whereby p53 status aects b-pol protein levels is not immediately clear. One possibility is that b-pol may be regulated by p53, a seemingly reasonable hypothesis based on the long-known ®nding that b-pol is a DNA damage-inducible gene (DDI), and that a number of DDI genes exhibit a p53-mediated component in their regulation. Another possibility is that complex formation of b-pol and p53 might aect the stability of b-pol, and that the stabilizing interaction is defective in p53-mutants and in p53-null cells. Indeed, b-pol polymerase activity was adversely aected in extracts prepared from p53-de®cient cells (Zhou et al., 2001) . To distinguish between these possibilities, we examined b-pol mRNA expression in p53+and p537 cells. No dierences were observed, leading us to favor the latter hypothesis. Indeed, the observed interaction of p53 and b-pol might predicate eects on stability of one or both proteins. The stability of p53 protein is known to be enhanced by DNA binding (Okorokov and Milner, 1999) . It therefore seems probable that the putative p53/b-pol complex may be stabilized by binding to DNA damage sites, a stabilizing interaction that would not occur in p53-null cells.
Cells derived from mice lacking b-pol genes exhibit a striking BER defect and sensitivity to base-damaging agents (Wilson and Kunkel, 2000) . The defect associated with loss of p53 is more modest, perhaps because p53-de®cient cells still express residual b-pol protein (Figure 4b) , at least as detected after MMS treatment. One would predict that complete loss of bpol, in b-pol-null mice, to result in a more severe BER de®cit (Fortini et al., 2000) .
Implications for carcinogenesis
In contrast to p53-mediated apoptosis and cell cycle arrest responses, much less is known about the regulation of DNA repair pathways by p53. We hypothesize that DNA repair defects such as the BER defect reported herein will be found to contribute to a large extent to the enhanced carcinogenesis associated with p53 loss. This would be especially true in p53-mutant cell types that evade apoptosis, e.g. lymphoid, in contrast to the cells used in the current study in which the p53-de®cient cells are actually more sensitive to DNA damage (Lackinger and Kaina, 2001 ; and results not shown). Hence, the need to balance cell death and DNA repair may be an important determinant of whether base damage lesions become ®xed as mutations, or whether cells are eliminated by apoptosis, depending on cell type (Brown and Wouters, 1999) .
Implications for chemotherapeutics
A number of cancer chemotherapeutic drugs are DNAdamaging agents in which a p53-regulated component in repair of their respective damages is foreseen (Fan et al., 1995; Hawkins et al., 1996; Seo et al., 2001) . Current ®ndings showing sensitivity of p53 defective cells to the base-damaging agent MMS (Lackinger and Kaina, 2001) , suggest that at least some p53-de®cient cancers may be preferentially sensitive to chemotherapeutic base-damaging agents e.g. cyclophosphamide, similar to MMS produce DNA damage that is repaired by BER. There have been only a few studies investigating the role of p53 in response to DNAdamaging chemotherapeutic agents, in the treatment of epithelial cancers (Seo et al., 2001) . These types of cancers are not intrinsically prone to undergo apoptosis (Brown and Wouters, 1999) suggesting that genotoxic stress is being repaired at a sucient rate. Our study and work by others (Oer et al., 2001a; Zhou et al., 2001) provides evidence that p53 is playing a role in BER and NER pathways, in cells that are wild-type for p53. Furthering our understanding of p53 involvement in DNA repair is likely to yield better therapeutic regimens for treatment of various cancers.
Materials and methods
Cell lines
We used isogenic matched pairs of cell lines carrying wildtype p53, and derivatives in which p53 function was abrogated by the introduction of a dominant-negative p53 mutant allele (codon 143 valine to alanine; Kastan et al., 1992) . Isogenic pairs of RKO human colon carcinoma and MCF7 human breast cancer lines have been used in previous studies (Kastan et al., 1992; Smith et al., 1995; Fan et al., 1995) . In addition, primary mouse embryo ®broblasts (MEFs) derived from p53 wild-type and p53-null mouse embryos at 13 days gestation, were utilized (Smith et al., 2000) . Each respective pair of cell lines exhibited comparable doubling times of approximately 24 h.
Single-cell alkaline electrophoretic (comet) assays
After treatments for the indicated time, the cells (10 4 ± 5610 4 ) were directly embedded in 0.5% agarose (Sigma, St. Louis, MO, USA) and spread on a Comet Slide (Trevigen, Inc., Gaithersburg, MD, USA). The cells were lysed with cold lysing solution (2.5 M NaCl, 1% Triton X-100, 1% sodium lauryl sarcosine, 10 mM Tris base, and 100 mM EDTA pH 10) for 30 min. Subsequently, cells were exposed to alkaline solution (300 mM NaOH, 1 mM EDTA, pH 13.0+0.1) for 30 min in order to allow for DNA unwinding, and then electrophoresis was performed in cold alkaline solution (300 mM NaOH, 1 mM EDTA) for 25 min (1 volt/cm, 250 mA). After electrophoresis, slides were neutralized in Tris buer (0.4 M, pH 7.4), and stained with SYBR Green Staining Solution (diluted 1 : 10 000; Trevigen). For quanti®cation, we use ®rst a visual scoring system (Collins et al., 1995) under¯uorescence microscopy (Carl Zeiss, Germany). Two hundred comets on each slide were classi®ed according to the relative intensity of¯uorescence in the tail: I (none, 55%); II (low, 5 ± 20%); III (medium, 20 ± 40%), IV (high, 40 ± 95%); V (total, 495%). For evaluation of DNA damage (arbitrary units), each classi®ed comet is given a value of 0 ± 4 (from undamaged [I] , 0, to maximally damaged [V], 4). Thus, the total score for 200 comets could range from 0 (all undamaged) to 800 (all maximally damaged). Per cent remaining MMS damage was calculated by comparison with the total score (100%) of initial DNA induced by MMS treatment (200 mM, 2 h). Second, we used an image analysis system (Morris et al., 1998) . Over 50 images of stained nuclei in random and non-overlapping ®elds were captured using confocal microscopic imaging system LSM-421 (Carl Zeiss, Germany) at each determination. Images were then analysed with Version 6.1 of NIH Image (available from: http://rsb.info.nih.gov/nih-image) and a macro written for the NIH Image program (Morris et al., 1998) . For evaluation of DNA damage, comet tail moment was computed as the integrated density in the comet tail multiplied by the distance from the center of the nucleus to the center of mass of the tail. Some cell loss (5 ± 15%) was observed due to trypsinization and embedding.
Flow cytometry
RKO and RKO-mut p53 cells were treated with 200 mM MMS, then processed for¯ow cytometry as described (Fan et al., 1995) . After 0, 2 and 6 h, cells were ®xed in 70% ethanol and stained with 50 mg/mL propidium bromide. Flow cytometric pro®les were determined using a Becton-Dickinson FACScan and analysed with CellFit software.
APE endonuclease activity assays
Assays were performed as previously described (Evans et al., 2000) . Brie¯y, cells were suspended in 0.5 mL harvesting buer (PBS containing 2 mM DTT), kept on ice and pulsesonicated. Debris was removed by centrifugation at 14 000 r.p.m. at 48C for 10 min. Protein concentrations were determined by the Bradford method. The substrate for APE cleavage consisted of a 26 base pair oligonucleotide containing a single tetrahydrofuran (THF) residue in the center, which was end-labeled by polynucleotide kinase in the presence of 50 mCi g-32 P-ATP. The radiolabeled strand was then annealed to the complementary strand in 10 mM Tris/ HCl pH 7.5, 10 mM MgCl 2 , 1 mM EDTA in a 908C water bath cooled to room temperature overnight. Annealed oligos were puri®ed by excising from a non-denaturing polyacrylamide gel and puri®ed by a Centrex MF micro®lter followed by ethanol precipitation. APE cleavage assays were conducted using 0.5 to 5 mg of cellular proteins in a 20 mL reaction mixture containing 50 mM HEPES, 50 mM KCl, 10 mM MgCl 2 , 1% BSA, 0.05% Triton X at 378C for 15 min. Cleaved products migrate at 13 bp upon denaturing electrophoresis in 20% polyacrylamide/urea gels, which were dried and exposed to X-ray ®lm or phosphorimager cassettes.
Immunoblotting of BER proteins
All immunoblots were conducted as in Smith et al. (1995) . Antibodies were as follows: mouse monoclonal antibody to APE (Ab-166C; Novus Biologicals, Littleton, CO, USA); anti-PCNA (Ab PC10; Oncogene Science Inc, Boston, MA, USA); Fen-1 (rabbit polyclonal; Trevigen, Inc, Gaithersburg, MD, USA); and b-polymerase (mouse monoclonal antibody 18S; NeoMarkers, Fremont, CA, USA). Detection was with horseradish peroxidase conjugated secondary antibodies (Sigma, St. Louis, MO, USA) and enhanced chemiluminescence (Pierce, Rockford, IL, USA).
Abbreviations MMS, methyl methanesulfonate; BER, base excision repair; AP, apurinic site; APE, apurinic/apyrimidinic endonuclease; b-pol, DNA-polymerase beta
